Dapsone ( DrugBank: Dapsone )

---

5 diseases

ID	Disease name (Link within this page)	Number of trials
35	Pemphigus	1
42	Polyarteritis nodosa	1
60	Aplastic anemia	2
84	Sarcoidosis	1
162	Pemphigoid	1

35. Pemphigus

---

Clinical trials : 99 /  Drugs : 124 - (DrugBank : 36) / Drug target genes : 23 - Drug target pathways : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00429533 (ClinicalTrials.gov)	November 1996	29/1/2007	Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris	A Prospective Randomized Placebo-Controlled Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance Phase Pemphigus Vulgaris	Pemphigus Vulgaris	Drug: Dapsone	Jacobus Pharmaceutical	NULL	Terminated	18 Years	80 Years	Both	48	Phase 2	United States

42. Polyarteritis nodosa

---

Clinical trials : 15 /  Drugs : 26 - (DrugBank : 16) / Drug target genes : 26 - Drug target pathways : 105

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02939573 (ClinicalTrials.gov)	January 1, 2017	18/10/2016	A Randomized Multicenter Study for Isolated Skin Vasculitis	A Randomized Multicenter Study for Isolated Skin Vasculitis	Primary Cutaneous Vasculitis;Cutaneous Polyarteritis Nodosa;IgA Vasculitis;Henoch-Schönlein Purpura	Drug: Colchicine;Drug: Dapsone;Drug: Azathioprine	University of Pennsylvania	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);National Center for Advancing Translational Sciences (NCATS);Office of Rare Diseases (ORD)	Recruiting	18 Years	N/A	All	90	Phase 2	United States;Canada;Japan

60. Aplastic anemia

---

Clinical trials : 245 /  Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00960050 (ClinicalTrials.gov)	June 2009	14/8/2009	Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone	Dapsone Induced Methemoglobinemia Study (DIMS)	Leukemia;Lymphoma;Methemoglobinemia;Nonmalignant Neoplasm	Genetic: polymorphism analysis;Other: laboratory biomarker analysis;Other: medical chart review;Procedure: assessment of therapy complications	Vanderbilt-Ingram Cancer Center	National Cancer Institute (NCI)	Active, not recruiting	N/A	22 Years	Both	173		United States
2	NCT00993694 (ClinicalTrials.gov)	January 2009	9/10/2009	Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone	Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia	Chronic Myeloproliferative Disorders;Leukemia;Lymphoma;Lymphoproliferative Disorder;Methemoglobinemia;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Neoplasms;Nonmalignant Neoplasm	Drug: chemotherapy;Drug: dapsone;Other: medical chart review;Procedure: assessment of therapy complications	Vanderbilt University	National Cancer Institute (NCI)	Completed	N/A	18 Years	All	41	N/A	United States

84. Sarcoidosis

---

Clinical trials : 149 /  Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00000596 (ClinicalTrials.gov)	June 1978	27/10/1999	Diffuse Fibrotic Lung Disease		Lung Diseases;Pulmonary Fibrosis;Sarcoidosis	Drug: prednisone;Drug: cyclophosphamide;Drug: dapsone	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	18 Years	N/A	Both		Phase 2	NULL

162. Pemphigoid

---

Clinical trials : 90 /  Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04744623 (ClinicalTrials.gov)	September 30, 2020	2/2/2021	Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone	Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone	Benign Mucous Membrane Pemphigoid	Drug: large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP	Tanta University	NULL	Active, not recruiting	40 Years	60 Years	All	10	Phase 2/Phase 3	Egypt

Back to top